APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases, including oedematous respiratory failure, acute lung injury, primary graft dysfunction, high altitude pulmonary oedema and pseudohypoaldosteronism type

APEPTICO's SOLNATIDE peptides have been delivered clinical proof of concept in various Phase II trials in treatment of pulmonary oedema in mechanically ventilated patients with acute respiratory dysfunction (ARDS) and in patients with primary graft dysfunction following lung transplantation.

By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies.